Vanguard Personalized Indexing Management LLC Acquires 6,790 Shares of Cencora, Inc. $COR

Vanguard Personalized Indexing Management LLC grew its holdings in shares of Cencora, Inc. (NYSE:COR) by 25.4% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 33,506 shares of the company’s stock after buying an additional 6,790 shares during the period. Vanguard Personalized Indexing Management LLC’s holdings in Cencora were worth $10,047,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Obermeyer Wealth Partners raised its position in Cencora by 1.3% in the 1st quarter. Obermeyer Wealth Partners now owns 2,724 shares of the company’s stock valued at $758,000 after buying an additional 36 shares during the last quarter. Grove Bank & Trust raised its position in Cencora by 4.3% in the 2nd quarter. Grove Bank & Trust now owns 879 shares of the company’s stock valued at $264,000 after buying an additional 36 shares during the last quarter. U.S. Capital Wealth Advisors LLC raised its position in Cencora by 0.4% in the 2nd quarter. U.S. Capital Wealth Advisors LLC now owns 8,547 shares of the company’s stock valued at $2,563,000 after buying an additional 38 shares during the last quarter. Monument Capital Management increased its position in shares of Cencora by 2.4% during the 2nd quarter. Monument Capital Management now owns 1,637 shares of the company’s stock valued at $491,000 after purchasing an additional 38 shares during the last quarter. Finally, Cromwell Holdings LLC increased its position in shares of Cencora by 9.5% during the 1st quarter. Cromwell Holdings LLC now owns 450 shares of the company’s stock valued at $125,000 after purchasing an additional 39 shares during the last quarter. 97.52% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Cencora

In other Cencora news, CEO Robert P. Mauch sold 5,097 shares of the firm’s stock in a transaction dated Thursday, September 18th. The stock was sold at an average price of $290.00, for a total value of $1,478,130.00. Following the completion of the transaction, the chief executive officer owned 39,274 shares in the company, valued at $11,389,460. This trade represents a 11.49% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Chairman Steven H. Collis sold 31,350 shares of the firm’s stock in a transaction dated Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total value of $9,087,111.00. Following the completion of the transaction, the chairman owned 305,913 shares of the company’s stock, valued at approximately $88,671,942.18. This represents a 9.30% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 55,993 shares of company stock valued at $16,292,923 in the last quarter. 10.80% of the stock is owned by corporate insiders.

Cencora Stock Up 1.2%

COR stock opened at $318.01 on Monday. The company has a debt-to-equity ratio of 3.64, a quick ratio of 0.53 and a current ratio of 0.90. The company has a market capitalization of $61.66 billion, a price-to-earnings ratio of 32.72, a PEG ratio of 1.49 and a beta of 0.63. Cencora, Inc. has a fifty-two week low of $221.95 and a fifty-two week high of $319.68. The stock has a fifty day moving average of $296.99 and a 200-day moving average of $291.87.

Cencora (NYSE:COR) last posted its quarterly earnings results on Wednesday, August 6th. The company reported $4.00 earnings per share for the quarter, topping the consensus estimate of $3.79 by $0.21. The company had revenue of $80.66 billion during the quarter, compared to the consensus estimate of $80.34 billion. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The firm’s quarterly revenue was up 8.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $3.34 EPS. As a group, equities research analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Friday, August 15th were paid a dividend of $0.55 per share. The ex-dividend date was Friday, August 15th. This represents a $2.20 annualized dividend and a dividend yield of 0.7%. Cencora’s dividend payout ratio is presently 22.63%.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the company. Evercore ISI set a $340.00 target price on Cencora in a research report on Wednesday. Wells Fargo & Company raised their target price on Cencora from $337.00 to $354.00 and gave the company an “overweight” rating in a research report on Wednesday, August 13th. Jefferies Financial Group raised their target price on Cencora from $275.00 to $300.00 and gave the company a “hold” rating in a research report on Monday, June 30th. Wall Street Zen lowered Cencora from a “buy” rating to a “hold” rating in a research report on Saturday. Finally, Morgan Stanley set a $330.00 target price on Cencora and gave the company an “equal weight” rating in a research report on Wednesday, July 16th. Nine investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Cencora has an average rating of “Moderate Buy” and an average target price of $320.00.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.